Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Oxeia Biopharmaceuticals.

    Client Virtual Booth

    OXEIA BIOPHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Oxeia Biopharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    9920 Pacific Heights Blvd., Suite 150 San Diego, CA 92121-4361
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oxeiabiopharma.com/
    Linkedin
    Linkedin
    Twitter
    Twitter
    https://twitter.com/oxeiabio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oxeia Announces Positive Interim Results of Phase 2 Trial For OXE103 For the Treatment of Concussions

    Details:

    OXE103 is synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier and is now being tested in humans to potentially treat concussions by addressing underlying neuro-metabolic dysfunction and axonal injury.


    Lead Product(s): Human Ghrelin

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OXE103

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: University of Kansas Medical Center

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 03, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oxeia Biopharmaceuticals, Inc. Announces Initiation Of Phase 2 Trial For OXE103 For The Treatment Of Concussions

    Details:

    The Randomized, placebo controlled phase 2 study aims to reduce symptom burden with OXE103 treatment. Measures of cognition and balance will also be tracked to provide objective assessment of recovery.


    Lead Product(s): Human Ghrelin

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OXE103

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 21, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search